Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

More than a third of US adults prescribed opioids in 2015

The United States needs to curb excessive opioid prescribing and improve access to pain management techniques, suggests a new government study.

Read More »

New Research Shows 99 Percent of Life Science Companies Still Need to Unify Clinical Applications

It’s no longer a question of if, but when. The life sciences industry has begun its journey to unify applications with the aim of driving greater efficiency across the end-to-end clinical landscape.

Read More »

Express Scripts to cover Mylan’s EpiPen, exclude rivals

Pharmacy benefit manager Express Scripts Holding Co. said it would favor drugmaker Mylan Inc.’s versions of the EpiPen lifesaving allergy treatment over the allergy auto-injectors of other companies.

Read More »

U.S. FDA to review Teva and Celltrion’s cancer biosimilar drug

Teva Pharmaceutical Industries and South Korea’s Celltrion said the U.S. Food and Drug Administration has accepted for review a biologics application for a biosimilar drug to treat breast cancer.

Read More »

J&J RA drug sirukumab raises safety concerns

There were more deaths in patients taking J&J’s experimental rheumatoid arthritis drug sirukumab than among those taking a placebo, FDA staff reviewers said.

Read More »

LabCorp Scoops Up CRO for $1.2 Billion

Clinical diagnostics company LabCorp announced it is buying private contract research organization Chiltern for $1.2 billion.

Read More »

FDA Panel Votes to Recommend Dynavax’s Hepatitis B Vaccine; Hepsilav Can Compete With GlaxoSmithKline’s Engerix-B

A U.S. Food and Drug Administration advisory committee gave a thumb’s-up recommendation for Dynavax Technologies Corporation’s Heplisav-B hepatitis B vaccine.

Read More »

Abilify Maintena Approved by FDA for Maintenance Monotherapy Treatment of Bipolar I Disorder

Otsuka Pharmaceutical and H. Lundbeck’s Abilify Maintena (aripiprazole) was approved by the U.S. FDA for the maintenance monotherapy treatment of bipolar I disorder in adults.

Read More »

AbbVie’s profit beats analysts’ expectations

U.S. drugmaker AbbVie Inc. reported Q2 2017 earnings that edged past analysts’ expectations, helped by robust demand for the company’s flagship RA drug Humira.

Read More »

Merck cyber attack will hurt profits

The international cyber attack Merck & Co. suffered in June halted some of the company’s manufacturing and other operations and cut its profit forecast for 2017.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom